Enrico Pelz
Viersen, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 23, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 30, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial.
Journal: Molecular cancer
Published: September 24, 2024
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: July 25, 2024
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
Journal: International journal of molecular sciences
Published: July 03, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 18, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 13, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: December 15, 2021
Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.
Journal: The journal of pathology. Clinical research
Published: September 21, 2021
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet.
Journal: Breast care (Basel, Switzerland)
Published: July 29, 2020
Granulomatous Mastitis: A Therapeutic and Diagnostic Challenge.
Journal: Breast care (Basel, Switzerland)
Published: February 26, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Journal: International journal of cancer
Published: November 20, 2018
Last Updated: 09/26/2026